UPDATED Jun 17, 2023
Investing in companies that think about the future will generate eco-friendly products and sustainable returns. As consumers become more environmentally-aware, demand will increase for these companies' products.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
LLAILungLife AI | UKĀ£0.38 | 23.0% | -74.6% | UKĀ£9.6m | UKĀ£2.26 | PS510.5x | E23.7% | n/a | ||
PYCPhysiomics | UKĀ£0.02 | 0% | -45.9% | UKĀ£1.9m | n/a | PS2.3x | E10.7% | n/a | ||
HCMHUTCHMED (China) | UKĀ£2.19 | 14.8% | 18.6% | UKĀ£1.9b | UKĀ£4.33 | PS5.6x | E53.8% | n/a | ||
OXBOxford Biomedica | UKĀ£4.70 | 2.0% | 13.3% | UKĀ£453.6m | UKĀ£10.72 | PS3.2x | E13.9% | n/a | ||
PRTCPureTech Health | UKĀ£2.34 | -2.3% | 58.5% | UKĀ£648.6m | UKĀ£5.85 | PS53.2x | E-20.8% | n/a | ||
ONTOxford Nanopore Technologies | UKĀ£2.24 | -9.1% | -31.1% | UKĀ£1.9b | UKĀ£3.43 | PS9.3x | E24.0% | n/a | ||
BVXPBioventix | UKĀ£37.25 | 0.3% | 4.9% | UKĀ£194.4m | UKĀ£43.00 | PE23.1x | E0.9% | 4.3% | ||
NIOXNIOX Group | UKĀ£0.62 | -0.8% | 96.8% | UKĀ£260.5m | n/a | PE18.5x | E-2.9% | n/a | ||
AVCTAvacta Group | UKĀ£0.99 | -9.2% | 1.5% | UKĀ£268.8m | UKĀ£2.07 | PS27.9x | E-4.4% | n/a | ||
CLSCConviction Life Sciences | UKĀ£1.00 | n/a | n/a | UKĀ£0 | n/a | n/a | n/a | n/a | ||
APOLApollon Formularies | UKĀ£0.0016 | 0% | -91.1% | UKĀ£1.2m | n/a | PS6.2x | n/a | n/a | ||
OBDOxford BioDynamics | UKĀ£0.11 | -15.0% | -35.0% | UKĀ£15.8m | n/a | PS54.6x | n/a | n/a | ||
FABFusion Antibodies | UKĀ£0.087 | 29.6% | -81.0% | UKĀ£5.2m | n/a | PS1.2x | E19.4% | n/a | ||
HELDHellenic Dynamics | UKĀ£0.00094 | -18.3% | n/a | UKĀ£11.8m | n/a | n/a | n/a | n/a | ||
CIZCizzle Biotechnology Holdings | UKĀ£0.024 | -1.1% | 38.2% | UKĀ£8.6m | n/a | PB3.2x | n/a | n/a | ||
MAXMaxRets Ventures | UKĀ£0.25 | 0% | -18.0% | UKĀ£3.7m | n/a | PB7.4x | n/a | n/a | ||
N4PN4 Pharma | UKĀ£0.017 | 0% | -33.3% | UKĀ£4.0m | n/a | PB1.9x | n/a | n/a | ||
ANAAnanda Developments | UKĀ£0.0053 | -12.5% | -16.0% | UKĀ£15.1m | n/a | PB243.3x | n/a | n/a | ||
SBTXSkinBioTherapeutics | UKĀ£0.13 | -1.5% | -37.1% | UKĀ£22.6m | n/a | PS174.1x | n/a | n/a | ||
OKYOOKYO Pharma | UKĀ£0.91 | -31.7% | -63.6% | UKĀ£23.2m | n/a | PE-3.5x | n/a | n/a | ||
IXIIXICO | UKĀ£0.18 | 1.4% | -50.7% | UKĀ£8.9m | n/a | PE64.4x | E-91.0% | n/a | ||
POLBPoolbeg Pharma | UKĀ£0.091 | 9.0% | 95.7% | UKĀ£45.5m | n/a | PB2.5x | E-14.2% | n/a | ||
OCTPOxford Cannabinoid Technologies Holdings | UKĀ£0.011 | -8.7% | 20.0% | UKĀ£10.1m | n/a | PB1x | n/a | n/a | ||
SCLPScancell Holdings | UKĀ£0.14 | -1.6% | -0.9% | UKĀ£116.6m | n/a | PS22.1x | E-53.6% | n/a |